Interactions between Formulation R and Halothane

Halothane has a moderate potential interaction with Arrhythmia.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.

The phenylephrine topical in Formulation R has a moderate potential interaction with Benign Prostatic Hyperplasia.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

The phenylephrine topical in Formulation R has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

Halothane has a moderate potential interaction with Cerebral Vascular Disorder.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.

The phenylephrine topical in Formulation R has a moderate potential interaction with Cerebrovascular Insufficiency.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

The phenylephrine topical in Formulation R has a moderate potential interaction with Diabetes Mellitus.

Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

Halothane has a moderate potential interaction with Heart Block.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.

The phenylephrine topical in Formulation R has a moderate potential interaction with Hyperthyroidism.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

Halothane has a moderate potential interaction with Hypotension.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.

Halothane has a moderate potential interaction with Ischemic Heart Disease.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.

The phenylephrine topical in Formulation R has a moderate potential interaction with Prostate Tumor, Benign.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

Halothane has a moderate potential interaction with Pseudotumor Cerebri.

Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid. Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine. Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.